Drug Profile
BI BTK 1
Alternative Names: BI-BTK-1Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lupus nephritis